我院2013-2015年住院患者抗凝血药应用合理性分析

发布时间：2019-05-27 17:15

【摘要】：目的:为抗凝血药临床合理使用提供参考。方法:从医院信息系统提取我院2013-2015年住院患者抗凝血药使用的医嘱信息,计算和分析该类药品的销售金额、用药频度(DDDs)、日均费用(DDC)以及各科室使用情况。结果:2013-2015年,低分子肝素钙注射液(6 000 AXa IU)、依诺肝素钠注射液(6 000 AXa IU)、达肝素钠注射液(5 000 IU)和利伐沙班片(10 mg)的金额比呈上升趋势,那屈肝素钙注射液(6 150、4 100 AXa IU)和磺达肝癸钠注射液(2.5 mg)的金额比呈下降趋势。那屈肝素钙注射液(4 100 AXa IU)、达肝素钠注射液(5 000 IU)和依诺肝素钠注射液(6 000 AXa IU)的DDDs位居前3位。利伐沙班片的DDC值最高,为167.60~180.25元。那屈肝素钙注射液(6 150、4 100 AXa IU)、低分子肝素钙注射液(6 000 AXa IU)、磺达肝癸钠注射液(2.5 mg)和华法林钠片(3 mg)3年内使用同步性较好,B/A值为0.50~1.50。血管外科的利伐沙班销售金额及使用率均居第1位。结论:结合医院疾病谱及各种药品的特点和不良反应,我院近3年抗凝血药使用趋于合理,但其使用情况仍应作为常规药学监测内容。
[Abstract]:Objective: to provide reference for clinical rational use of anticoagulant. Methods: the information of anticoagulant used by inpatients in our hospital from 2013 to 2015 was extracted from hospital information system, and the sales amount of anticoagulant drugs, the average daily cost of (DDDs), and the use of anticoagulant drugs in various departments were calculated and analyzed. Results: from 2013 to 2015, the amount ratio of low molecular weight heparin calcium injection (6000 AXa IU), enoheparin sodium injection (6000 AXa IU),) heparin sodium injection (5000 IU) and rivasaban tablet (10 mg) showed an upward trend. The amount ratio of Naproheparin calcium injection (6 150, 4 100 AXa IU) and sulfondachan decyl sodium injection (2. 5 mg) showed a downward trend. The DDDs of Nadroheparin calcium injection (4 100 AXa IU),) and enoheparin sodium injection (6 000 AXa IU) were in the top three. The DDC value of rivasaban tablets was the highest (167.60 鈮，

本文编号：2486334